The medicinal product subject to prescription Zinc-D-gluconate shall not be included in Annex I to Delegated Regulation (EU) 2016/161 and shall not be exempted from the requirement to bear the safety features referred to in Article 54, point (o), of Directive 2001/83/EC.
資料由法律人 LawPlayer整理提供·EU law / curated by LawPlayer from EUR-Lex
Commission Decision (EU) 2021/1125 of 8 July 2021 refusing to include the medicinal product subject to prescription Zinc-D-gluconate in the list of medicinal products that shall not bear the safety features referred to in Article 54, point (o), of Directive 2001/83/EC of the European Parliament and of the Council (Text with EEA relevance)
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
Cite this act
Commission Decision (EU) 2021/1125 of 8 July 2021 refusing to include the medicinal product subject to prescription Zinc-D-gluconate in the list of medicinal products that shall not bear the safety features referred to in Article 54, point (o), of Directive 2001/83/EC of the European Parliament and of the Council (Text with EEA relevance) (EUR-Lex). Retrieved via LawPlayer, https://lawplayer.com/eu/act/32021D1125
© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.
本頁資料來源:EUR-Lex·整理提供:法律人 LawPlayer· lawplayer.com